Profile of:
Marleen Van de Sande
Marleen van de Sande graduated from the Faculty of Medicine of the University of Amsterdam in 2004. In January 2012 she obtained her doctorate entitled ‘Clinical and Molecular Classification of Very Early Arthritis Patients’ at the University of Amsterdam. She completed her specialist training in rheumatology in 2016. Since February 2016 she has been working as a rheumatologist at the Department of Rheumatology and Clinical Immunology of the AMC in Amsterdam, the Netherlands, and she has started a translational research line on the immunopathogenesis of the earliest phases of spondyloarthritis. She has received a personal research grant from the Dutch Research Counsil NWO talent programme VENI in 2019. Since 2020 she is the chairman of the Spondyloarthritis workgroup of the Dutch Society for Rheumatology.
Full name: Marleen Van de Sande
Current country: Netherlands
Membership level: Full
Type of membership: Member
Number of publications: 5
Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis. (2020)
https://pubmed.ncbi.nlm.nih.gov/32933547/
Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31941804/
mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo. (2020)
https://pubmed.ncbi.nlm.nih.gov/30353386/
Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial. (2019)
https://pubmed.ncbi.nlm.nih.gov/31521192/
First-degree relatives of axial spondyloarthritis patients of the pre-SpA cohort would consider using medication in a preventive setting. (2019)
https://pubmed.ncbi.nlm.nih.gov/30353386/
